Drug Insights

Is Ubrogepant approved by the FDA?

27 June 2024
3 min read

Yes, Ubrogepant, marketed under the brand name Ubrelvy, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Ubrogepant on December 23, 2019. This medication is used for the acute treatment of migraine attacks with or without aura in adults.

What is Ubrogepant?

Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It is specifically designed to treat migraine headaches once they start but is not used to prevent migraines. It works by blocking the CGRP protein, which is involved in migraine pathophysiology, thereby reducing pain and other migraine symptoms such as nausea, light sensitivity, and sound sensitivity.

Uses of Ubrogepant

Ubrogepant is prescribed for the acute treatment of migraine attacks in adults. It can be taken with or without food, and most patients can take a second dose two hours after the first if needed. However, it is not intended for the preventive treatment of migraine headaches.

Who Should Not Take Ubrogepant?

Patients should avoid Ubrogepant if they are taking strong CYP3A4 inhibitors, such as:

  • Ketoconazole
  • Clarithromycin
  • Itraconazole

Patients should consult their healthcare provider to ensure it is safe to take Ubrogepant with their current medications.

Precautions and Interactions

Before taking Ubrogepant, patients should inform their healthcare provider about any existing medical conditions, especially liver or kidney problems. It is also crucial to discuss any other medications being taken, including prescription, over-the-counter drugs, vitamins, and herbal supplements, as several medications can interact with Ubrogepant.

Side Effects of Ubrogepant

Common side effects include:

  • Nausea
  • Sleepiness

More severe side effects should be reported to a healthcare provider immediately. Patients may also report side effects to the FDA at 1-800-FDA-1088.

Pregnancy and Breastfeeding

The effects of Ubrogepant on pregnant women and breastfeeding mothers are not well established. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before starting Ubrogepant.

Storage

Ubrogepant should be stored at room temperature between 68ºF to 77ºF (20ºC to 25ºC) and kept out of reach of children.

Conclusion

Ubrogepant (Ubrelvy) is an FDA-approved medication effective for the acute treatment of migraines in adults. Approved on December 23, 2019, it offers relief from migraine symptoms but is not intended for migraine prevention. Patients should discuss their full medical history and current medications with their healthcare provider to ensure safe use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Grants Accelerated Approval for KRAZATI® and Cetuximab Combo in Advanced KRAS G12C Mutated CRC
Latest Hotspot
3 min read
FDA Grants Accelerated Approval for KRAZATI® and Cetuximab Combo in Advanced KRAS G12C Mutated CRC
27 June 2024
Bristol Myers Squibb reveals that the U.S. FDA has granted accelerated approval for KRAZATI® (adagrasib) combined with Cetuximab for adults with previously treated, advanced, or metastatic colorectal cancer (CRC) with the KRAS G12C mutation.
Read →
Is Enhertu approved by the FDA?
Drug Insights
3 min read
Is Enhertu approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) first approved Enhertu on December 20, 2019, for the treatment of HER2-positive breast cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 27
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 27
27 June 2024
Jun 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Is Lumateperone approved by the FDA?
Drug Insights
3 min read
Is Lumateperone approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Caplyta on December 20, 2019, for the treatment of schizophrenia in adults.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.